1Banchereau J, Steinman RM. Dendritic cells and the control of immunity [ J ]. Nature, 1998,392 (6673) :245-252.
2Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SC1D mouse/ human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[ J ]. J Exp Med, 1991,174 ( 1 ) : 139-149.
6Verneris MR, Kornacker M, MailanderV, et al. Resistance of ex vivo expanded CD3 + CD56 + T cells to Fas-mediated apoptosis [ J ]. Cancer lmmunol Immunother,2000,49(6 ) :335-345.
7Schmidt J,Klempp C,Buchler MW,et al. Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo [ J ]. Cancer Immunol Immunother,2006,55 ( 1 ) :31-38.
8Marten A, Ziske C, Schottker B,et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations[ J]. J Immunother,2001, 24(6) :502-510.
5[1]Peck K, Sher YP, Shih JY, et al. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients[J]. Cancer Res, 1998, 58(13) :2761
6[2]Funaki NO, Tanaka J, Ohshio G, et al. Cytokeratin 20 mRNA in peripheral venous blood of colorectal carcinoma patients[J]. Br J Cancer. 1998, 77(8) :1327
7[3]Banchereau J, Steinman R. Dendritic cells and the control of immunity[J]. Nature, 1998, 392:245
8[4]Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy[J]. Blood Rev, 1999,13(1):51
9[5]Schmidt-Wolf I, Negrin R, Kiem H, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J3. J Exp Med,1991, 174:139
10[6]Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations[J]. J Immunol, 2001, 24(6) :502
